Danaher to Launch First AI Autonomous Lab to Speed Discovery 8x

Danaher announced plans to launch an AI autonomous lab at Abcam that will use robotics and artificial intelligence to generate affinity reagents and discover antibodies up to 8x faster than current methods. The facility will combine technology from Danaher subsidiaries including Cytiva and Beckman Coulter Life Sciences with automation from Automata to establish a continuous design-make-test-learn loop, with operations scaling in early 2027. Shares of Danaher rose 1.3% in premarket trading after the announcement.